These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 6147830

  • 1. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV, Arnt J, Hyttel J, Svendsen O.
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological differentiation of dopamine D-1 and D-2 antagonists after single and repeated administration.
    Christensen AV, Arnt J, Svendsen O.
    Psychopharmacology Suppl; 1985; 2():182-90. PubMed ID: 2860659
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics.
    Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O.
    Life Sci; 1984 Apr 16; 34(16):1529-40. PubMed ID: 6144029
    [Abstract] [Full Text] [Related]

  • 4. Biochemical and pharmacological differentiation of neuroleptic effect on dopamine D-1 and D-2 receptors.
    Hyttel J, Christensen AV.
    J Neural Transm Suppl; 1983 Apr 16; 18():157-64. PubMed ID: 6135740
    [Abstract] [Full Text] [Related]

  • 5. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA.
    J Pharmacol Exp Ther; 1995 Oct 16; 275(1):101-13. PubMed ID: 7562537
    [Abstract] [Full Text] [Related]

  • 6. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J.
    Eur J Pharmacol; 1985 Jul 11; 113(1):79-88. PubMed ID: 2931283
    [Abstract] [Full Text] [Related]

  • 7. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan 11; 280(1):73-82. PubMed ID: 8996184
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA, Awouters FH, Meert TF, Schellekens KH, Niemegeers CJ, Janssen PA.
    J Pharmacol Exp Ther; 1992 Jan 11; 260(1):146-59. PubMed ID: 1370538
    [Abstract] [Full Text] [Related]

  • 9. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E, Tonello C, Imhof R, Scherschlicht R, da Prada M, Carruba MO.
    J Pharmacol Exp Ther; 1993 Jul 11; 266(1):97-105. PubMed ID: 8101225
    [Abstract] [Full Text] [Related]

  • 10. Classification of neuroleptics: implications for tardive dyskinesia.
    Christensen AV.
    Pol J Pharmacol Pharm; 1985 Jul 11; 37(3):295-309. PubMed ID: 2866499
    [Abstract] [Full Text] [Related]

  • 11. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
    Nemeroff CB, Luttinger D, Hernandez DE, Mailman RB, Mason GA, Davis SD, Widerlöv E, Frye GD, Kilts CA, Beaumont K, Breese GR, Prange AJ.
    J Pharmacol Exp Ther; 1983 May 11; 225(2):337-45. PubMed ID: 6682440
    [Abstract] [Full Text] [Related]

  • 12. Is dopamine antagonism a requisite of neuroleptic activity?
    Greenblatt EN, Coupet J, Rauh E, Szucs-Myers VA.
    Arch Int Pharmacodyn Ther; 1980 Nov 11; 248(1):105-19. PubMed ID: 6111298
    [Abstract] [Full Text] [Related]

  • 13. Some central effects of opioid antagonists. Part I.
    Skorupska M, Langwiński R.
    Pol J Pharmacol Pharm; 1989 Nov 11; 41(5):401-11. PubMed ID: 2577060
    [Abstract] [Full Text] [Related]

  • 14. [Behavioral pharmacological investigation and clinical consideration of the inhibitory potencies of psychotropic drugs against the D-1 and D-2 dopamine receptors].
    Kazawa T.
    Yakubutsu Seishin Kodo; 1986 Sep 11; 6(3):327-37. PubMed ID: 2949452
    [Abstract] [Full Text] [Related]

  • 15. Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.
    Arnt J, Bøgesø KP, Christensen AV, Hyttel J, Larsen JJ, Svendsen O.
    Psychopharmacology (Berl); 1983 Sep 11; 81(3):199-207. PubMed ID: 6139838
    [Abstract] [Full Text] [Related]

  • 16. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S.
    J Pharmacol Exp Ther; 2007 Jan 11; 320(1):486-96. PubMed ID: 17038512
    [Abstract] [Full Text] [Related]

  • 17. Blockade of D-1 dopamine receptors in the medial prefrontal cortex produces delayed effects on pre- and postsynaptic indices of dopamine function in the nucleus accumbens.
    Vezina P, Blanc G, Glowinski J, Tassin JP.
    Synapse; 1994 Feb 11; 16(2):104-12. PubMed ID: 8197574
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of methylphenidate-induced behaviors in rats: differences among neuroleptics.
    Koek W, Colpaert FC.
    J Pharmacol Exp Ther; 1993 Oct 11; 267(1):181-91. PubMed ID: 7901392
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT, Caprathe BW, Christoffersen CL, Corbin AE, Jaen JC, Ninteman FW, Pugsley TA, Serpa KA, Shih YH, Whetzel SZ.
    J Pharmacol Exp Ther; 1993 Sep 11; 266(3):1177-89. PubMed ID: 8103791
    [Abstract] [Full Text] [Related]

  • 20. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB, Fuxe K, Werge T, Gerlach J.
    Behav Pharmacol; 2002 Dec 11; 13(8):639-44. PubMed ID: 12478214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.